Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Dr. Chris Heger (Bio-Techne) and Dr. Mike Piazza (Nicoya Lifesciences) will illustrate a fast, simple icIEF fractionation and digital SPR workflow that provides in-depth characterization of the charge ...